Nurix Therapeutics Inc (NRIX) — Cash Flow Reinvestment Rate

Latest as of November 2023: 0.64x

Nurix Therapeutics Inc (NRIX) has a Cash Flow Reinvestment Rate of 0.64x as of November 2023, reinvesting $16.96 Million (capex $2.58 Million plus investments $-14.37 Million) from operating cash flow of $26.69 Million. Check NRIX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.64x
(Capex + Investments) / Operating CF

Total Reinvested

$16.96 Million
Capex + Investments

Operating Cash Flow

$26.69 Million
USD

Capital Expenditures

$2.58 Million
USD

Nurix Therapeutics Inc Cash Flow Reinvestment Rate (2019–2019)

Historical reinvestment intensity for Nurix Therapeutics Inc across 1 annual periods. Explore NRIX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Nurix Therapeutics Inc (2019–2019)

Year-by-year capital reinvestment analysis for Nurix Therapeutics Inc. For live market cap and broader valuation context, see NRIX market cap overview.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2019 16.89x $10.15 Million $601.00K $1.65 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow